Back to mobile site

Baird Reiterates Outperform Rating on Jazz Pharmaceuticals (JAZZ)

November 3, 2026 3:48 AM EST Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $280.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login